Show simple item record

dc.contributoren-US
dc.creatorPatel, Brijesh
dc.creatorChhalotiya, Usmangani K.
dc.creatorPatel, Sandip B.
dc.date2018-04-25
dc.date.accessioned2019-04-16T16:42:48Z
dc.date.available2019-04-16T16:42:48Z
dc.identifierhttps://www.jcchems.com/index.php/JCCHEMS/article/view/582
dc.identifier.urihttp://revistaschilenas.uchile.cl/handle/2250/42374
dc.description A sensitive, accurate, precise and reproducible high performance thin layer chromatographic method has been developed for the estimation of clofarabine in their pharmaceutical dosage form. The objective of this validation of an analytical procedure is to demonstrate that the drug Clofarabine is suitable for its intended purpose. The analytical method development recommends the quality, purity and specificity of the drug. Clofarabine injection form during the manufacturing process and hence the standard of drug may not vary, which produce the desirable therapeutic effect.TLC aluminum plates pre-coated with silica gel 60F254used as the stationary phase, while toluene: methanol (8:2, v/v) used as mobile phase. The Rf value was observe 0.34± 0.05 for clofarabine. The densitometric analysis was carried out in absorbance mode at 266 nm. The method was linear in the range of 50 – 1000 ng/spot for clofarabine. The method was validated as per ICH guideline. The limit of detection and limit of quantitation were found to be 17.60ng/spot and 53.35 ng/spot, respectively for clofarabine.The proposed method was successfully applied to the estimation of clofarabinein the pharmaceutical dosage form. Clofarabine was subjected to acid and alkali hydrolysis, chemical oxidation, wet hydrolysis, dry heat degradation and sun light degradation. The degradants peaks were well resolved from the pure drug peak with significant difference in their Rf values. Stressed samples were assayed using proposed TLC method.en-US
dc.formatapplication/pdf
dc.languageeng
dc.publisherSociedad Chilena de Químicaen-US
dc.relationhttps://www.jcchems.com/index.php/JCCHEMS/article/view/582/216
dc.rightsCopyright (c) 2018 Journal of the Chilean Chemical Societyen-US
dc.rightshttp://creativecommons.org/licenses/by-nc-sa/4.0en-US
dc.sourceJournal of the Chilean Chemical Society; Vol 63, No 1 (2018): Journal of the Chilean Chemical Societyen-US
dc.source0717-9707
dc.subjectClofarabine; HPTLC; Validation; Analysis; Force Degradationen-US
dc.titleESTIMATION OF NEWER ANTI-CANCER DRUG CLOFARABINE IN THEIR PHARMACEUTICAL DOSAGE FORM BY STABILITY INDICATING TLC METHODen-US
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.typeen-US


This item appears in the following Collection(s)

Show simple item record